KR100775095B1 - Whitening composition for external applications to the skin containing tyrosol derivatives - Google Patents

Whitening composition for external applications to the skin containing tyrosol derivatives Download PDF

Info

Publication number
KR100775095B1
KR100775095B1 KR1020060116740A KR20060116740A KR100775095B1 KR 100775095 B1 KR100775095 B1 KR 100775095B1 KR 1020060116740 A KR1020060116740 A KR 1020060116740A KR 20060116740 A KR20060116740 A KR 20060116740A KR 100775095 B1 KR100775095 B1 KR 100775095B1
Authority
KR
South Korea
Prior art keywords
cream
skin
whitening
tyrosol
integer
Prior art date
Application number
KR1020060116740A
Other languages
Korean (ko)
Inventor
이찬우
김한성
김덕희
장이섭
구경아
이범종
손은미
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to KR1020060116740A priority Critical patent/KR100775095B1/en
Application granted granted Critical
Publication of KR100775095B1 publication Critical patent/KR100775095B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

A skin external composition for whitening skin containing tyrosol derivatives is provided to suppress pigment permeation, improve spots and freckles, and whiten the skin by inhibiting melanin formation without side effects. A skin external composition for whitening skin contains 0.001-10 wt.% of tyrosol derivatives represented by the formula(1), wherein Ar1 is the structural formula(1-a), Ar2 is the structural formula(1-b), m is an integer of 1 or 2 and n is an integer of 2 or 3, and is formulated as soft lotion, astringent lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, gel, pack, powder, body lotion, body cream, body oil or body essence.

Description

타이로졸 유도체를 함유하는 피부 미백용 화장료{Whitening composition for external applications to the skin containing tyrosol derivatives}Whitening composition for external applications to the skin containing tyrosol derivatives}

본 발명은 하기 화학식 1의 타이로졸 유도체 및 이를 유효성분으로 함유하여 부작용 없이 우수한 미백 효과가 있는 피부 미백용 화장료에 관한 것이다.The present invention relates to a cosmetic composition for skin whitening having an excellent whitening effect without the side effects by containing a tyrosol derivative of the general formula (1) as an active ingredient.

[화학식 1][Formula 1]

Figure 112006086349910-pat00004
Figure 112006086349910-pat00004

(상기 식에서 Ar1

Figure 112006086349910-pat00005
이고, Ar2
Figure 112006086349910-pat00006
이며, k는 0 내지 2의 정수, m은 1 내지 2의 정수, n은 2 내지 3의 정수이다.)Where Ar 1 is
Figure 112006086349910-pat00005
And Ar 2 is
Figure 112006086349910-pat00006
K is an integer of 0 to 2, m is an integer of 1 to 2, n is an integer of 2 to 3)

사람의 피부색은 멜라닌 색소를 만드는 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께 및 카로티노이드, 빌리루빈 등 인체 내외의 색소 함유 유무와 같은 여러 요인들에 의해 결정되며 그 중 멜라노사이트에서 타이로시나제 등의 여러 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소가 가장 중요하다. 멜 라닌 색소의 형성에는 유전적 요인, 호르몬 분비, 스트레스 등과 관련된 생리적 요인 및 자외선 조사 등과 같은 환경적 요인이 영향을 미친다. 멜라닌은 피부에 존재하여 자외선 등으로부터 신체를 보호하는 중요한 기능을 가지고 있지만 멜라닌이 과잉생산 됨으로써 기미, 주근깨 등을 형성할 뿐 아니라 피부노화를 촉진하며 피부암 유발에도 중요한 작용을 하는 것으로 알려져 있다.Human skin color is determined by a number of factors, including the activity of melanocytes that make melanin, the distribution of blood vessels, the thickness of the skin, and the presence or absence of pigments inside and outside the body, such as carotenoids and bilirubin. The most important is a black pigment called melanin produced by the action of various enzymes such as cinnases. The formation of melanin pigment is influenced by genetic factors, physiological factors related to hormone secretion, stress, and environmental factors such as ultraviolet irradiation. Melanin is present in the skin and has an important function of protecting the body from ultraviolet rays, but it is known that melanin is overproduced to form spots, freckles, etc., promote skin aging, and also play an important role in inducing skin cancer.

기미, 주근깨, 색소침착 등과 같은 피부색소 이상침착 증상과 자외선 노출 등에 의해 발생된 과도한 멜라닌 색소 침착을 치료 또는 경감시켜주기 위해서 이전부터 아스코르빈산, 코지산, 알부틴, 하이드로퀴논, 글루타치온 또는 이들의 유도체, 타이로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합 사용하여 왔는데, 이들은 불충분한 미백효과, 피부에 대한 안전성 문제, 화장료에 배합시 제형 및 안정성 문제 등으로 인해 그 사용이 제한되고 있다.Ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione or derivatives thereof to treat or alleviate excessive melanin pigmentation caused by skin pigmentation abnormalities such as blemishes, freckles and pigmentation and UV exposure. In addition, substances having tyrosinase inhibitory activity have been used in cosmetics and pharmaceuticals, but their use is limited due to insufficient whitening effects, safety problems for skin, formulation and stability problems when formulated in cosmetics, and the like.

천연 유래 활성물질에 대한 유도체 합성을 통하여 안전성이 뛰어날 뿐만 아니라 여러 가지 효능을 나타낼 수 있으며 이에 따라 미백 물질의 좋은 검색 대상이 되며 따라서 종래부터 우수한 미백 효과는 물론 인체 피부에 대한 안전성을 모두 갖춘 천연유래 활성 물질 유도체를 통한 효능 물질 연구의 노력은 계속 되고 있다.It is not only excellent in safety but also can show various effects through synthesis of derivatives for natural-derived active substances. Therefore, it is a good search target for whitening substances. Therefore, it is natural-derived with both excellent whitening effect and safety for human skin. Efforts to research potent substances through active substance derivatives continue.

최근 Mary Ann Lila (Phytochemistry. 2006 67(21) : 2380-91), Dong Sheng Ming (Phytother Res. 2005 19(9):740-3)에 의하여 홍경천 유래의 페놀릭 화합물의 구조분석과 그 항산화 효능에 대하여 발표를 하였으며 여기에 파라-타이로졸도 포함되어 있다. 또한 천연 올리브오일 유래의 하이드록시 타이로졸(hydroxytyrosol)의 멜라닌 생성 억제능에 대한 선행 특허(US20030180833, US2003/0108651)가 존재 하고 있다. 홍경천에서 약리적으로 중요한 성분은 살리드로사이드(salidroside)와 p-타이로졸(p-tyrosol)로 알려져 있으며, 관절염, 통증, 폐결핵, 빈혈, 신경통, 간염, 저혈압에 약효가 좋으며, 강심, 진정, 조혈, 내한, 항염증 작용이 뛰어나 인삼보다 효능이 더 좋으면서도 인삼이 지닌 어떤 부작용도 없다는 장점을 가지고 있다. 성분들 중에서 p-타이로졸 (p-tyrosol)은 그 자체로 항산화 활성과 항염증 활성이 뛰어난 것으로 알려져 있다. 그러나 천연 유래의 타이로졸 또는 히드록시타이로졸은 미백 효과 측면에서도 충분히 우수한 효과를 나타내지 못하는 문제점이 있다.Recent structural analysis of phenolic compounds derived from Hong Kyung-cheon by Mary Ann Lila (Phytochemistry. 2006 67 (21): 2380-91) and Dong Sheng Ming (Phytother Res. 2005 19 (9): 740-3) And para-tyrosol. In addition, prior patents (US20030180833, US2003 / 0108651) exist for inhibiting melanogenesis of hydroxytyrosol derived from natural olive oil. Pharmacologically important ingredients in Rhodiola saline are known as salidroside and p-tyrosol. They are effective for arthritis, pain, pulmonary tuberculosis, anemia, neuralgia, hepatitis and hypotension. Hematopoietic, cold-resistant, anti-inflammatory action is more effective than ginseng, but has the advantage of no side effects of ginseng. Among the components, p-tyrosol is known to be excellent in antioxidant and anti-inflammatory activity by itself. However, there is a problem in that the tyrosol or hydroxytyrosol derived from nature does not exhibit a sufficiently good effect in terms of the whitening effect.

따라서 새로운 구조를 가지는 화합물을 유도체화 하여 피부 부작용 없이 우수한 미백 효과를 나타내는 피부 미백 화장료의 개발이 필요한 실정이다.Therefore, it is necessary to develop a skin whitening cosmetic that exhibits excellent whitening effect without skin side effects by derivatizing a compound having a new structure.

천연 유래의 타이로졸 또는 히드록시타이로졸은 인체 피부에 안전성을 가지는 화합물이고 미백 효과가 있는 것으로 알려져 있으나 그 자체 물질로는 미백 효과가 미미한 문제점이 있었다.Naturally derived tyrosol or hydroxytyrosol is a compound having safety on human skin and is known to have a whitening effect, but the material itself has a problem of insignificant whitening effect.

따라서, 본 발명의 목적은 인체피부에 안전하게 사용될 수 있을 뿐만 아니라 미백 효과가 우수한 새로운 타이로졸 유도체를 유효성분으로 함유하여 부작용 없이 우수한 미백 효과가 있는 피부 미백용 화장료를 제공하는 데 있다.Therefore, it is an object of the present invention to provide a cosmetic for whitening skin having excellent whitening effect without side effects by containing a new tyrosol derivative that can be used safely on the human skin as well as excellent whitening effect as an active ingredient.

본 발명자들은 우수한 미백효과를 나타내면서 동시에 인체 피부에 대한 안전성을 갖춘 새로운 미백제에 대하여 연구한 결과 히드록시페닐기를 갖는 카르복실산과의 에스테르화 반응에 의해 제조된 새로운 구조의 타이로졸(tyrosol) 유도체가 뛰어난 색소 침착 저해 효과는 물론 인체 피부에 대해 우수한 안전성을 지니고 있음을 발견하고 본 발명을 완성하게 되었다.The present inventors studied a new whitening agent having excellent whitening effect and safety for human skin. As a result, a new structure of a tyrosol derivative prepared by esterification with a carboxylic acid having a hydroxyphenyl group was obtained. The present invention has been found to have excellent pigmentation inhibitory effect as well as excellent safety for human skin.

본 발명은 하기 화학식 1로 표시되는 타이로졸 유도체를 유효성분으로 함유하는 피부 미백용 화장료를 제공한다.The present invention provides a cosmetic for skin whitening containing a tyrosol derivative represented by the following formula (1) as an active ingredient.

[화학식 1][Formula 1]

Figure 112006086349910-pat00007
Figure 112006086349910-pat00007

(상기 식에서 Ar1

Figure 112006086349910-pat00008
이고, Ar2
Figure 112006086349910-pat00009
이며, k는 0 내지 2의 정수, m은 1 내지 2의 정수, n은 2 내지 3의 정수이다.)Where Ar 1 is
Figure 112006086349910-pat00008
And Ar 2 is
Figure 112006086349910-pat00009
K is an integer of 0 to 2, m is an integer of 1 to 2, n is an integer of 2 to 3)

이하 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명에 따른 피부 미백용 화장료에 유효 성분으로 함유되는 타이로졸 유도체는 하기 화학식 1의 구조를 가진다.The tyrosol derivative contained as an active ingredient in the skin whitening cosmetics according to the present invention has a structure represented by the following Chemical Formula 1.

[화학식 1] [Formula 1]

Figure 112006086349910-pat00010
Figure 112006086349910-pat00010

(상기 식에서 Ar1

Figure 112006086349910-pat00011
이고, Ar2
Figure 112006086349910-pat00012
이며, k는 0 내지 2의 정수, m은 1 내지 2의 정수, n은 2 내지 3의 정수이다.)Where Ar 1 is
Figure 112006086349910-pat00011
And Ar 2 is
Figure 112006086349910-pat00012
K is an integer of 0 to 2, m is an integer of 1 to 2, n is an integer of 2 to 3)

보다 바람직하게는 상기 화학식 1 에서 Ar1은 하기 치환체로부터 선택되고,More preferably Ar 1 in Formula 1 is selected from the following substituents,

Figure 112006086349910-pat00013
Figure 112006086349910-pat00013

Ar2는 하기 치환체로부터 선택된다.Ar 2 is selected from the following substituents.

Figure 112006086349910-pat00014
Figure 112006086349910-pat00014

또한, 상기 화학식 1의 타이로졸 유도체는 하기 구조식의 화합물을 포함한다.In addition, the tyrosol derivative of Formula 1 includes a compound of the following structural formula.

Figure 112006086349910-pat00015
Figure 112006086349910-pat00015

Figure 112006086349910-pat00016
Figure 112006086349910-pat00016

Figure 112006086349910-pat00017
Figure 112006086349910-pat00017

Figure 112006086349910-pat00018
Figure 112006086349910-pat00018

Figure 112006086349910-pat00019
Figure 112006086349910-pat00019

Figure 112006086349910-pat00020
Figure 112006086349910-pat00020

상기 타이로졸 유도체는 하기 반응식 1에서 제시되는 제조방법에 의해 제조될 수 있다. 하기 반응식 1은 알코올 화합물과 카르복실산 화합물의 에스테르화 반응에 의해 화학식 1의 타이로졸 유도체를 제조하는 방법으로서 에스테르화 시약으로는 DCC(dicyclohexylcarbodiimide) 등을 사용할 수 있다.The tyrosol derivative may be prepared by the preparation method shown in Scheme 1 below. Reaction Scheme 1 below is a method of preparing a tyrosol derivative of Chemical Formula 1 by esterification of an alcohol compound and a carboxylic acid compound, and as the esterification reagent, dicyclohexylcarbodiimide (DCC) may be used.

[반응식 1]Scheme 1

Figure 112006086349910-pat00021
Figure 112006086349910-pat00021

(상기 식에서 Ar1, Ar2 및 k는 화학식 1에서 정의한 바와 같다.)(Wherein Ar 1 , Ar 2 and k are as defined in Formula 1)

그러나, 상기 제조방법에 한정되는 것은 아니고 공지의 유기 합성 반응을 사용하여 다양하게 제조될 수 있다.However, it is not limited to the above production method and may be variously prepared using a known organic synthesis reaction.

상기 화학식 1의 타이로졸 유도체의 함량에 제한을 둘 필요는 없으나 화장료 조성물 총 중량에 대하여 0.001~20중량%, 보다 바람직하게는 0.001~10중량%, 보다 더 바람직하게는 0.01~5중량%로 함유하는 것이 좋다. 이는 0.001중량% 미만에서는 그 효과를 기대할 수 없고, 20중량% 초과에서는 안전성 또는 제형 상의 제조에 어려움이 있기 때문이다.It is not necessary to limit the content of the tyrosol derivative of Formula 1, but 0.001 to 20% by weight, more preferably 0.001 to 10% by weight, even more preferably 0.01 to 5% by weight based on the total weight of the cosmetic composition It is good to contain. This is because the effect can not be expected at less than 0.001% by weight, there is a difficulty in the safety or formulation formulation over 20% by weight.

또한, 본 발명의 피부 미백용 화장료 조성물은 타이로졸 유도체 외에 본 발명이 목적으로 하는 미백 효과를 손상시키지 않는 범위 내에서 바람직하게는 상기 미백 효과에 상승효과를 줄 수 있는 다른 미백 성분 등을 함유하는 것도 무방하다. 이와 같은 미백 성분으로는 알부틴, 아스코빅산 유도체 등을 들 수 있다.In addition, the cosmetic composition for skin whitening of the present invention, in addition to the tyrosol derivative, preferably contains other whitening ingredients and the like that can give a synergistic effect to the whitening effect within a range that does not impair the whitening effect of the present invention. It is okay to do it. Arbutin, an ascorbic acid derivative, etc. are mentioned as such a whitening component.

또한, 본 발명의 미백 화장료는 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 젤, 팩, 파우더, 보디로션, 보디크림, 보디오일, 보디에센스 등의 화장료로 제형화 될 수 있다.In addition, the whitening cosmetic of the present invention is not particularly limited in the formulation, for example, supple cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, It may be formulated into a cosmetic such as cleansing water, gel, pack, powder, body lotion, body cream, body oil, body essence and the like.

이하, 실시예 및 시험예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명하나 하기 실시예에 의해서 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to Examples and Test Examples, but the scope of the present invention is not limited by the following Examples.

[제조예 1] 2-히드록시펜에틸 3,4,5-트리히드록시벤조에이트의 합성Preparation Example 1 Synthesis of 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate

Figure 112006086349910-pat00022
Figure 112006086349910-pat00022

THF 20mL에 갈산(gallic acid)(0.02mol)와 2-히드록시펜에틸 알코올(3-hydroxyphenethyl alcohol)(0.025mol)를 넣고 녹인다. CaCl2가 채워진 관을 장착한 플라스크에 용액을 넣는다. 빙욕을 장착한 후 DCC 용액(DCC 0.02mol / CH2Cl2 10mL)을 천천히 가하였다. 빙욕을 제거한 후, 상온에서 5시간 동안 교반하여 반응시켰다. 반응종결 후, 반응물을 여과하여 우레아를 제거하였다. 여액을 물로 여러 번 세척하고, 5% 아세트산으로 더 세척하였다. 다시 물로 세척하고, MgSO4로 건조시킨 다음 용매를 제거하였다. 반응물을 실리카겔 컬럼크로마토그래피 분리한 후 건조시켰다. 생성물을 클로로포름으로 씻어낸 후 여과하여 건조시켰으며, 그 결과 상아색 2-히드록시펜에틸 3,4,5-트리히드록시벤조에이트(1.5095g, 수율:26%)를 얻었다.Dissolve gallic acid (0.02mol) and 2-hydroxyphenethyl alcohol (0.025mol) in 20mL THF. The solution is placed in a flask equipped with a CaCl 2 filled tube. After mounting the ice bath DCC solution (DCC 0.02mol / CH 2 Cl 2 10mL) was slowly added. After removing the ice bath, the reaction was stirred at room temperature for 5 hours. After completion of the reaction, the reaction was filtered to remove urea. The filtrate was washed several times with water and further with 5% acetic acid. Washed again with water, dried over MgSO 4 and the solvent was removed. The reaction was separated by silica gel column chromatography and dried. The product was washed with chloroform and then filtered and dried to obtain an ivory 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate (1.5095 g, yield: 26%).

1H NMR(Acetone-d6, δ) : 8.21(s, OH, 4H), 7.22(s, Ar, 1H), 7.06(s, Ar, 2H), 6.83(m, Ar, 2H), 6.78(d, Ar, 2H), 4.43(t, 2H), 3.02(t, 2H). 1 H NMR (Acetone-d 6 , δ): 8.21 (s, OH, 4H), 7.22 (s, Ar, 1H), 7.06 (s, Ar, 2H), 6.83 (m, Ar, 2H), 6.78 ( d, Ar, 2H), 4.43 (t, 2H), 3.02 (t, 2H).

[제조예 2] 3-히드록시펜에틸 3,4,5-트리히드록시벤조에이트의 합성Preparation Example 2 Synthesis of 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate

Figure 112006086349910-pat00023
Figure 112006086349910-pat00023

3-히드록시펜에틸 알코올(3-hydroxyphen ethyl alcohol)(0.025mol)을 사용하는 것을 제외하고는 실시예 1과 동일한 방법으로 제조하여 상아색 3-히드록시펜에틸 3,4,5-트리히드록시벤조에이트 1.655g(수율:28.5%)을 얻었다.Ivory 3-hydroxyphenethyl 3,4,5-trihydroxy was prepared in the same manner as in Example 1 except using 3-hydroxyphenethyl alcohol (0.025 mol). 1.655 g (yield: 28.5%) of benzoate were obtained.

1H NMR(Acetone-d6, δ) : 8.26(s, OH, 4H), 7.08(s, Ar, 1H), 7.01(s, Ar, 2H), 6.83(m, Ar, 1H), 6.67(d, Ar, 2H), 4.36(t, 2H), 2.97(t, 2H). 1 H NMR (Acetone-d 6 , δ): 8.26 (s, OH, 4H), 7.08 (s, Ar, 1H), 7.01 (s, Ar, 2H), 6.83 (m, Ar, 1H), 6.67 ( d, Ar, 2H), 4.36 (t, 2H), 2.97 (t, 2H).

[시험예 1] [Test Example 1]

B16/F10 B16 / F10 멜라노마Melanoma 세포(melanoma cell)을The melanoma cell 이용한 멜라닌 생성  Melanin production 억제능Inhibitory ability 평가 evaluation

제조예 1과 2로부터 제조된 타이로졸 유도체를 시험물질로 하여 10 % FBS가 함유된 DMEM으로 6-웰 플레이트(6-well plate)(melanin 정량)에 2 X 104 cell/well(final volume 3 ml), 96-웰 플레이트(96-well plate)(MTT assay)에 2 X 103 cell/well(final volume 200 ul)로 넣고 37 ℃, 5% CO2 인큐베이터(incubator)(MCO-20AIC, Sanyo)에서 24시간 배양한다. 배양 후 배지를 제거하고 10% FBS, 2 uM α-MSH(Melanocyte stimulating hormone), 2 mM 테오피 린(theophylline)이 함유된 DMEM 배지를 새로운 배지로 사용하고 배지에 시험물질을 첨가하여 3일간 매일 처리한다. 5일째에 6-웰 플레이트(6-well plate)에서 배양된 배지를 제거하고 0.25% 트립신-EDTA(trypsin-EDTA)(Sigma Chemical Co.)용액을 처리하여 세포 펠렛(pellet)을 회수하고 1.5 ml 튜브(tube)로 옮겨 10,000rpm으로 10분간 원심분리하여 상등액을 제거한다. 얻어진 pellet을 60 ℃에서 건조시킨후 1N NaOH 100 ul를 넣어 세포내 멜라닌을 녹인다. 이 용액을 PBS로 희석시킨 다음 엘리사 리더(ELISA reader) 475nm에서 흡광도를 측정하여 시료의 멜라닌 생성저해율을 구한다. 상기 타이로졸 유도체를 첨가하지 않은 세포를 대조군으로 하여 대조군에서의 멜라닌 함량과 비교하여 실험물질의 멜라닌 생성 저해정도를 측정하여 미백효과를 측정하였다. 하기 수학식 1에 따라 멜라닌 생성 억제율을 계산하여 그 결과를 표 1에 나타내었다.Using the tyrosol derivatives prepared in Preparation Examples 1 and 2 as test substance, 2 X 10 4 cells / well (final volume) in a 6-well plate (melanin quantitative determination) with DMEM containing 10% FBS. 3 ml), in a 96-well plate (MTT assay) in 2 X 10 3 cell / well (final volume 200 ul) and 37 ℃, 5% CO 2 incubator (MCO-20AIC, Incubate for 24 hours in Sanyo. After incubation, remove the medium and use DMEM medium containing 10% FBS, 2 uM α-MSH (Melanocyte stimulating hormone), 2 mM theophylline as a fresh medium and add test substances to the medium for 3 days every day. Process. On day 5, cultured medium was removed from a 6-well plate and treated with 0.25% trypsin-EDTA (Sigma Chemical Co.) solution to recover the cell pellet and 1.5 ml. Transfer to a tube (centrifuge) at 10,000 rpm for 10 minutes to remove the supernatant. After drying the pellet obtained at 60 ℃ 100N of 1N NaOH to dissolve the intracellular melanin. Dilute this solution with PBS and measure the absorbance at 475 nm of ELISA reader to determine the rate of melanin inhibition in the sample. As a control, the cells without addition of the tyrosol derivative were measured for the whitening effect by measuring the degree of inhibition of melanin production of the test substance compared with the melanin content in the control. According to Equation 1 below to calculate the melanin production inhibition is shown in Table 1 the results.

수학식 1Equation 1

Figure 112006086349910-pat00024
Figure 112006086349910-pat00024

[표 1] 멜라닌 생성 억제 효과[Table 1] Melanin production inhibitory effect

Figure 112006086349910-pat00025
Figure 112006086349910-pat00025

상기 표 1로부터 알 수 있는 바와 같이, 본 발명에 따른 실시예 1 및 실시예 2의 화합물이 파라-타이로졸(p-tyrozol) 및 코지산의 경우에 비해서 미백효과가 월등히 우수함을 알 수 있다.As can be seen from Table 1, the compounds of Examples 1 and 2 according to the present invention can be seen that the whitening effect is superior to the case of para-tyrosol (p-tyrozol) and koji acid. .

한편, 본 발명의 타이로졸 유도체를 함유하는 피부 미백용 화장료의 제형은 임의로 선택할 수 있으며, 종래의 화장료 제형인 영양크림, 영양로션, 맛사지크림, 영양에센스, 유연화장수 등 여러 가지 형태로 제조할 수 있다. 하기 제형예서 사용한 폴리솔베이트는 유니크마(Uniquema)사 제품이고, 폴리아크릴산은 SNF사 제품명 Flogel 700을 사용하였고, 폴리비닐알코올은 쿠라레이(Kuraray)사 PVA-217을 사용하였다.On the other hand, the formulation of the skin whitening cosmetics containing the tyrosol derivative of the present invention can be arbitrarily selected, and can be prepared in various forms, such as nutrition cream, nutrition lotion, massage cream, nutrition essence, supple cosmetics which are conventional cosmetic formulations. Can be. Polysorbate used in the following formulation was manufactured by Uniquema, polyacrylic acid was used SNF product name Flogel 700, polyvinyl alcohol was used Kuraray (Kuraray) PVA-217.

[제형예 1] 영양화장수(밀크로션) Formulation Example 1 Nutritious Longevity (Milk Lotion)

하기의 표 2와 같이 타이로졸 유도체를 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.As shown in Table 2, nutrient-containing longevity containing a tyrosol derivative was prepared according to a conventional method.

[표 2]TABLE 2

Figure 112006086349910-pat00026
Figure 112006086349910-pat00026

[제형예 2] 유연화장수(스킨로션)Formulation Example 2 Softener (Skin Lotion)

하기의 표 3과 같이 타이로졸 유도체를 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.A flexible longevity containing a tyrosol derivative was prepared according to a conventional method as shown in Table 3 below.

[표 3]TABLE 3

Figure 112006086349910-pat00027
Figure 112006086349910-pat00027

[제형예 3] 영양크림Formulation Example 3 Nutrition Cream

하기의 표 4와 같이 타이로졸 유도체를 함유하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritive cream containing a tyrosol derivative was prepared according to a conventional method as shown in Table 4 below.

[표 4]TABLE 4

Figure 112006086349910-pat00028
Figure 112006086349910-pat00028

[제형예 4] 마사지크림Formulation Example 4 Massage Cream

하기의 표 5와 같이 타이로졸 유도체를 함유하는 마사지크림을 통상의 방법에 따라 제조하였다.A massage cream containing a tyrosol derivative was prepared according to a conventional method as shown in Table 5 below.

[표 5]TABLE 5

Figure 112006086349910-pat00029
Figure 112006086349910-pat00029

[제형예 5] 팩[Formulation Example 5] Pack

하기의 표 6과 같이 타이로졸 유도체를 함유하는 팩을 통상의 방법에 따라 제조하였다.A pack containing a tyrosol derivative was prepared according to a conventional method as shown in Table 6 below.

[표 6]TABLE 6

Figure 112006086349910-pat00030
Figure 112006086349910-pat00030

[제형예 6] 젤Formulation Example 6 Gel

하기의 표 7과 같이 타이로졸 유도체를 함유하는 젤을 통상의 방법에 따라 제조하였다.As shown in Table 7 below, a gel containing a tyrosol derivative was prepared according to a conventional method.

[표 7]TABLE 7

Figure 112006086349910-pat00031
Figure 112006086349910-pat00031

이상에서 설명한 바와 같이, 본 발명에 의해 제공되는 타이로졸 유도체를 유효성분으로 하는 피부 미백용 화장료는 인체 피부에 대한 안전성을 갖는 동시에 우수한 미백 효과를 제공한다.As described above, the skin whitening cosmetics using the tyrosol derivative provided by the present invention as an active ingredient have safety against human skin and provide excellent whitening effects.

Claims (5)

하기 화학식 1로 표시되는 타이로졸 유도체를 유효성분으로 함유하는 피부 미백용 화장료. Cosmetics for skin whitening containing a tyrosol derivative represented by the following formula (1) as an active ingredient. [화학식 1][Formula 1]
Figure 112007073992393-pat00043
Figure 112007073992393-pat00043
(상기 식에서 Ar1
Figure 112007073992393-pat00033
이고, Ar2
Figure 112007073992393-pat00034
이며, m은 1 내지 2의 정수, n은 2 내지 3의 정수이다.)
Where Ar 1 is
Figure 112007073992393-pat00033
And Ar 2 is
Figure 112007073992393-pat00034
M is an integer of 1 to 2, n is an integer of 2 to 3.)
제 1 항에 있어서,The method of claim 1, 상기 Ar1은 하기 치환체로부터 선택되고,Ar 1 is selected from the following substituents,
Figure 112006086349910-pat00035
Figure 112006086349910-pat00035
상기 Ar2는 하기 치환체로부터 선택되는Ar 2 is selected from the following substituents
Figure 112006086349910-pat00036
Figure 112006086349910-pat00036
것을 특징으로 하는 피부 미백용 화장료.Cosmetics for skin whitening, characterized in that.
제 2 항에 있어서,The method of claim 2, 하기 구조식으로부터 선택되는 것을 특징으로 하는 피부 미백용 화장료.Cosmetics for skin whitening, characterized in that selected from the following structural formula.
Figure 112006086349910-pat00037
Figure 112006086349910-pat00037
Figure 112006086349910-pat00038
Figure 112006086349910-pat00038
Figure 112006086349910-pat00039
Figure 112006086349910-pat00039
Figure 112006086349910-pat00040
Figure 112006086349910-pat00040
Figure 112006086349910-pat00041
Figure 112006086349910-pat00041
Figure 112006086349910-pat00042
Figure 112006086349910-pat00042
제 1 항에 있어서, The method of claim 1, 상기 타이로졸 유도체의 함량은 화장료 총 중량에 대하여 0.001 내지 10중량%인 것을 특징으로 하는 피부 미백용 화장료.The content of the tyrosol derivative is a skin whitening cosmetic, characterized in that 0.001 to 10% by weight relative to the total weight of the cosmetic. 제 1 항에 있어서, The method of claim 1, 상기 화장료는 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 젤, 팩, 파우더, 보디로션, 보디크림, 보디오일 또는 보디에센스로부터 선택되는 제형인 것을 특징으로 하는 피부 미백용 화장료.The cosmetics may include softening cream, astringent makeup, nutrition cream, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, gel, pack, powder, body lotion, body cream, body oil or A cosmetic for skin whitening, characterized in that the formulation is selected from body essences.
KR1020060116740A 2006-11-24 2006-11-24 Whitening composition for external applications to the skin containing tyrosol derivatives KR100775095B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020060116740A KR100775095B1 (en) 2006-11-24 2006-11-24 Whitening composition for external applications to the skin containing tyrosol derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060116740A KR100775095B1 (en) 2006-11-24 2006-11-24 Whitening composition for external applications to the skin containing tyrosol derivatives

Publications (1)

Publication Number Publication Date
KR100775095B1 true KR100775095B1 (en) 2007-11-08

Family

ID=39061588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020060116740A KR100775095B1 (en) 2006-11-24 2006-11-24 Whitening composition for external applications to the skin containing tyrosol derivatives

Country Status (1)

Country Link
KR (1) KR100775095B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030012562A (en) * 2001-08-01 2003-02-12 주식회사 웰스킨 Whitening composition containing rhodiola sachalinensis a. bor extraction
KR20070049582A (en) * 2005-11-08 2007-05-11 엥겔하드 리옹 에스.에이. Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions
KR20070075077A (en) * 2006-01-12 2007-07-18 인제대학교 산학협력단 Composition comprising tyrosol derivatives for anti oxidation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030012562A (en) * 2001-08-01 2003-02-12 주식회사 웰스킨 Whitening composition containing rhodiola sachalinensis a. bor extraction
KR20070049582A (en) * 2005-11-08 2007-05-11 엥겔하드 리옹 에스.에이. Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions
KR20070075077A (en) * 2006-01-12 2007-07-18 인제대학교 산학협력단 Composition comprising tyrosol derivatives for anti oxidation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
한국공개특허공보 10-2007-0049582
한국공개특허공보 10-2007-0075077
한국공개특허공보 특2003-0012562

Similar Documents

Publication Publication Date Title
CN111093621A (en) Cosmetic composition containing dendrobium officinale flower extract
EP2633886B1 (en) Compounds and mixtures influencing inflammatory states
KR20140060749A (en) Cosmetic composition comprising the extract of golden silkworm cocoon as active ingredient
KR100602684B1 (en) Cosmetic composition comprising extract of erigeron breviscapus for whitening
JP2007063191A (en) New bleaching agent
JP2010047497A (en) Elastin production promoting agent
KR20140095122A (en) A composition for inhibiting degradation of collagen or promoting synthesis of collagen comprising barley extract or eriodictyol
KR102056620B1 (en) External composition for skin containing Cannabis sativa extract
KR100775095B1 (en) Whitening composition for external applications to the skin containing tyrosol derivatives
KR101245563B1 (en) Agents for skin whitening containing Madecassoside
KR101430636B1 (en) Functional cosmetic composition comprising ginsenosides Rh2 and Rg3
KR100829819B1 (en) Whitening cosmetic composition for external applications to the skin containing panduratin derivatives
KR20120036417A (en) A cosmetic composition for skin whitening comprising the extract of saccharina japonica as active ingredient
KR100851044B1 (en) 3,5-dihydroxy benzamide derivatives having depigmenting activity and the whitening cosmetic composition containing the same
KR20080004742A (en) Composition for skin whitening containing diosgenin
KR101427027B1 (en) A Skin External Composition Containing Callus Extract Derived from Chaenomeles Sinensis
JPH08268863A (en) Tyrosinase biosynthesis promotor and hair cosmetic and sun-burn cosmetic
KR101521579B1 (en) Skin Whitening and Anti―oxidative Composition Containing Boesenbergia rotunda Extract
JP2011157319A (en) Melanin production inhibitor
KR20110063894A (en) Cosmetic composition containing narirutin
KR100682549B1 (en) Sesamol derivatives and process for preparing the same
KR101244653B1 (en) Compositions for Improving Skin Conditions Comprising Ginsenoside Rb3 as an Active Ingredient
KR101887957B1 (en) Composition containing epimedin extracted from genus epimedium plant
KR100561781B1 (en) Composition for skin whitening containing extract of Sinomenium acutum
KR20110064292A (en) Cosmetic composition containing rucinol and polygonum multiflorum extracts for skin whitening

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Publication of correction
FPAY Annual fee payment

Payment date: 20121017

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20131011

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20151030

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20161010

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20170928

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20181002

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20190926

Year of fee payment: 13